The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.

被引：0
作者：
O'Brien, N. A.
Browne, B. C.
Chow, L.
Ginther, C.
Bensadigh, B.
Arboleda, J.
Duffy, M. J.
Crown, J.
O'Donovan, N.
Slamon, D. J.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Dublin City Univ, Dublin 9, Ireland
[3] St Vincents Univ Hosp, Dublin 4, Ireland
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：160S / 160S
页数：1
相关论文
共 50 条
  • [31] NRF2 antioxidant signaling mediates the ability of PIM protein kinases to induce resistance of prostate cancer to PI3K inhibitor therapy.
    Song, Jin H.
    Leuvano, Libia A.
    Singh, Neha
    Kraft, Andrew S.
    CANCER RESEARCH, 2018, 78 (16) : 132 - 132
  • [32] Evaluation of the PI3K/pAkt pathway in breast carcinoma which are negative for ER, PR and HER-2/neu receptor expresssion
    Ricketts, RSJ
    Gupta, R
    Pazik, B
    Marconi, S
    Otis, CN
    MODERN PATHOLOGY, 2006, 19 : 40A - 41A
  • [33] Resistance to Endocrine Therapy in Estrogen Receptor-Positive (ER plus ) Breast Cancer Is Dependent upon Phosphatidylinositol-3 Kinase (PI3K) Signaling
    Miller, T. W.
    Fox, E. M.
    Gonzalez-Angulo, A. M.
    Hennessy, B. T.
    Mills, G. B.
    McKinley, E. T.
    Manning, H. C.
    Arteaga, C. L.
    CANCER RESEARCH, 2009, 69 (24) : 516S - 516S
  • [34] Evaluation of the PI3K/pAkt pathway in breast carcinoma which are negative for ER, PR and HER-2/neu receptor expresssion
    Ricketts, RSJ
    Gupta, R
    Pazik, B
    Marconi, S
    Otis, CN
    LABORATORY INVESTIGATION, 2006, 86 : 40A - 41A
  • [35] BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy.
    Solca, F
    Baum, A
    Guth, B
    Colbatzky, F
    Blech, S
    Amelsberg, A
    Himmelsbach, F
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9025S - 9025S
  • [36] HER-2 signaling through PI3′K is associated with breast cancer invasion into bone
    Ignatoski, K. M. W.
    Day, K. C.
    Sargent, E. E.
    Ethier, S. P.
    Day, M. L.
    Keller, E. T.
    CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 : 40 - 40
  • [37] Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors
    Engelman, Jeffrey A.
    Zejnullahu, Kreshnik
    Mitsudomi, Tetsuya
    Hyland, Courtney
    Park, Joon Oh
    Lindeman, Neal
    Gale, Christopher-Michael
    Zhao Xiaojun
    Christensen, James
    Rogers, Rogers M.
    Cappuzzo, Federico
    Mok, Tony
    Lee, Charles
    Bruce, Johnson E.
    Cantley, Lewis C.
    Janne, Pasi A.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S396 - S396
  • [38] HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment
    Li, Jiayao
    Xiao, Qian
    Bao, Yi
    Wang, Wenyu
    Goh, Jianyuan
    Wang, Panpan
    Yu, Qiang
    CELL CYCLE, 2019, 18 (13) : 1513 - 1522
  • [39] Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
    Poovassery, Jayakumar S.
    Kang, Jeffrey C.
    Kim, Dongyoung
    Ober, Raimund J.
    Ward, E. Sally
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 267 - 277
  • [40] Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond
    Sirico, M.
    Jacobs, F.
    Molinelli, C.
    Nader-Marta, Guilherme
    Debien, V.
    Dewhurst, H. Faith
    Palleschi, M.
    Merloni, F.
    Gianni, C.
    De Giorgi, U.
    de Azambuja, Evandro
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 200
12345